UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

The New England journal of medicine, 2020-04, Vol.382 (16), p.1497-1506

2020

Volltextzugriff (PDF)

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia

European archives of psychiatry and clinical neuroscience, 2023-10, Vol.273 (7), p.1543-1556

2023

Volltextzugriff (PDF)

Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans

Translational psychiatry, 2021-04, Vol.11 (1), p.228-228, Article 228

2021

Volltextzugriff (PDF)

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

CPT: pharmacometrics and systems pharmacology, 2021-10, Vol.10 (10), p.1245-1254

2021

Volltextzugriff (PDF)

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia

Clinical and translational science, 2023-06, Vol.16 (6), p.1063-1074

2023

Volltextzugriff (PDF)

TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding

Molecular metabolism (Germany), 2024-02, Vol.80, p.101883-101883, Article 101883

2024

Volltextzugriff (PDF)

Evaluation of OCT2‐mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia

Pharmacology research & perspectives, 2024-04, Vol.12 (2), p.e1191-n/a

2024

Volltextzugriff (PDF)

Challenges in the clinical development of non-D2 compounds for schizophrenia

Current medical research and opinion, 2023-03, Vol.39 (3), p.467-471

2023

Volltextzugriff (PDF)

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D 2 Receptor Mechanism of Action

The Journal of pharmacology and experimental therapeutics, 2019-10, Vol.371 (1), p.1-14

2019

Volltextzugriff (PDF)

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy

Schizophrenia (Heidelberg, Germany), 2023-08, Vol.9 (1), p.49-49, Article 49

2023

Volltextzugriff (PDF)

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

Journal of affective disorders, 2022-01, Vol.296, p.549-558

2022

Volltextzugriff (PDF)

Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders

Clinical pharmacology and therapeutics, 2021-09, Vol.110 (3), p.808-815

2021

Volltextzugriff (PDF)

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

Molecular psychiatry, 2021-06, Vol.26 (6), p.2562-2576

2021

Volltextzugriff (PDF)

Pharmacodynamic effects of a D-amino acid oxidase inhibitor indicate a spinal site of action in rat models of neuropathic pain

The Journal of pharmacology and experimental therapeutics, 2013-06, Vol.345 (3), p.502-511

2013

Volltextzugriff (PDF)

Review of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist Ulotaront: Part II—Summary of Initial Clinical Efficacy/Safety Results

CNS spectrums, 2023-04, Vol.28 (2), p.221-221

2023

Volltextzugriff (PDF)

Structural, Kinetic, and Pharmacodynamic Mechanisms of d‑Amino Acid Oxidase Inhibition by Small Molecules

Journal of medicinal chemistry, 2013-05, Vol.56 (9), p.3710-3724

2013

Volltextzugriff (PDF)

Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM)

Psychiatry research, 2020-12, Vol.294, p.113569-113569, Article 113569

2020

Volltextzugriff (PDF)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS

Clinical drug investigation, 2021-12, Vol.41 (12), p.1067-1073

2021

Volltextzugriff (PDF)

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia

Schizophrenia bulletin, 2018-04, Vol.44 (3), p.593-602

2018

Volltextzugriff (PDF)

A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression

Contemporary clinical trials, 2024-10, Vol.145, p.107644, Article 107644

2024

Volltextzugriff (PDF)

A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy

Sleep medicine, 2023-07, Vol.107, p.202-211

2023

Volltextzugriff (PDF)

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults

Neuropsychopharmacology (New York, N.Y.), 2015-11, Vol.40 (12), p.2745-2752

2015

Volltextzugriff (PDF)

Review of the TAAR1 Agonist Ulotaront: Part I—From Discovery to Clinic

CNS spectrums, 2023-04, Vol.28 (2), p.221-221

2023

Volltextzugriff (PDF)

TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner

Neuropsychopharmacology (New York, N.Y.), 2024-06, Vol.49 (7), p.1091-1103

2024

Volltextzugriff (PDF)

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS

Clinical drug investigation, 2022-12, Vol.42 (12), p.1113-1121

2022

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(90)
Bücher
(1)

Sprache

Englisch
(90)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia

Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia

TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding

Evaluation of OCT2‐mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia

Challenges in the clinical development of non-D2 compounds for schizophrenia

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D 2 Receptor Mechanism of Action

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

Pharmacodynamic effects of a D-amino acid oxidase inhibitor indicate a spinal site of action in rat models of neuropathic pain

Review of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist Ulotaront: Part II—Summary of Initial Clinical Efficacy/Safety Results

Structural, Kinetic, and Pharmacodynamic Mechanisms of d‑Amino Acid Oxidase Inhibition by Small Molecules

Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia

A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression

A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults

Review of the TAAR1 Agonist Ulotaront: Part I—From Discovery to Clinic

TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS

Suchergebnisse filtern